Literature DB >> 18483220

The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss.

Tamara Terzian1, Young-Ah Suh, Tomoo Iwakuma, Sean M Post, Manja Neumann, Gene A Lang, Carolyn S Van Pelt, Guillermina Lozano.   

Abstract

The p53 tumor suppressor is often disrupted in human cancers by the acquisition of missense mutations. We generated mice with a missense mutation at codon 172 that mimics the p53R175H hot spot mutation in human cancer. p53 homozygous mutant mice have unstable mutant p53 in normal cells and stabilize mutant p53 in some but not all tumors. To investigate the significance of these data, we examined the regulation of mutant p53 stability by Mdm2, an E3 ubiquitin ligase that targets p53 for degradation, and p16INK4a, a member of the Rb tumor suppressor pathway. Mice lacking Mdm2 or p16INK4a stabilized mutant p53, and revealed an earlier age of tumor onset than p53 mutant mice and a gain-of-function metastatic phenotype. Analysis of tumors from p53 homozygous mutant mice with stable p53 revealed defects in the Rb pathway. Additionally, ionizing radiation stabilizes wild-type and mutant p53. Thus, the stabilization of mutant p53 is not a given but it is a prerequisite for its gain-of-function phenotype. Since mutant p53 stability mimics that of wild-type p53, these data indicate that drugs aimed at activating wild-type p53 will also stabilize mutant p53 with dire consequences.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18483220      PMCID: PMC2377188          DOI: 10.1101/gad.1662908

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  57 in total

Review 1.  Post-translational modifications and activation of p53 by genotoxic stresses.

Authors:  E Appella; C W Anderson
Journal:  Eur J Biochem       Date:  2001-05

Review 2.  p53 modulation of the DNA damage response.

Authors:  E Scott Helton; Xinbin Chen
Journal:  J Cell Biochem       Date:  2007-03-01       Impact factor: 4.429

Review 3.  Coping with stress: multiple ways to activate p53.

Authors:  H F Horn; K H Vousden
Journal:  Oncogene       Date:  2007-02-26       Impact factor: 9.867

Review 4.  The oncogenic roles of p53 mutants in mouse models.

Authors:  Guillermina Lozano
Journal:  Curr Opin Genet Dev       Date:  2007-01-08       Impact factor: 5.578

5.  Overexpression of vascular endothelial growth factor-A165 enhances tumor angiogenesis but not metastasis during beta-cell carcinogenesis.

Authors:  Grainne Gannon; Stefano J Mandriota; Lin Cui; Danielle Baetens; Michael S Pepper; Gerhard Christofori
Journal:  Cancer Res       Date:  2002-01-15       Impact factor: 12.701

Review 6.  Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.

Authors:  A Sigal; V Rotter
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

7.  An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2.

Authors:  S C Evans; M Viswanathan; J D Grier; M Narayana; A K El-Naggar; G Lozano
Journal:  Oncogene       Date:  2001-07-05       Impact factor: 9.867

8.  Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo.

Authors:  T F Burns; E J Bernhard; W S El-Deiry
Journal:  Oncogene       Date:  2001-08-02       Impact factor: 9.867

9.  Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis.

Authors:  N E Sharpless; N Bardeesy; K H Lee; D Carrasco; D H Castrillon; A J Aguirre; E A Wu; J W Horner; R A DePinho
Journal:  Nature       Date:  2001-09-06       Impact factor: 49.962

10.  Oncogenic ras and p53 cooperate to induce cellular senescence.

Authors:  Gerardo Ferbeyre; Elisa de Stanchina; Athena W Lin; Emmanuelle Querido; Mila E McCurrach; Gregory J Hannon; Scott W Lowe
Journal:  Mol Cell Biol       Date:  2002-05       Impact factor: 4.272

View more
  183 in total

Review 1.  Mouse models of p53 functions.

Authors:  Guillermina Lozano
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-09       Impact factor: 10.005

2.  SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.

Authors:  D Li; N D Marchenko; U M Moll
Journal:  Cell Death Differ       Date:  2011-06-03       Impact factor: 15.828

3.  Allele-specific p53 mutant reactivation.

Authors:  Xin Yu; Alexei Vazquez; Arnold J Levine; Darren R Carpizo
Journal:  Cancer Cell       Date:  2012-05-15       Impact factor: 31.743

4.  Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway.

Authors:  Ricardo E Perez; Chad D Knights; Geetaram Sahu; Jason Catania; Vamsi K Kolukula; Daniel Stoler; Adolf Graessmann; Vasily Ogryzko; Michael Pishvaian; Christopher Albanese; Maria Laura Avantaggiati
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

5.  Building p53.

Authors:  Tamara Terzian; Guillermina Lozano
Journal:  Genes Dev       Date:  2010-10-15       Impact factor: 11.361

Review 6.  Making sense of ubiquitin ligases that regulate p53.

Authors:  Abhinav K Jain; Michelle Craig Barton
Journal:  Cancer Biol Ther       Date:  2010-10-01       Impact factor: 4.742

7.  Wild-type p53 controls cell motility and invasion by dual regulation of MET expression.

Authors:  Chang-Il Hwang; Andres Matoso; David C Corney; Andrea Flesken-Nikitin; Stefanie Körner; Wei Wang; Carla Boccaccio; Snorri S Thorgeirsson; Paolo M Comoglio; Heiko Hermeking; Alexander Yu Nikitin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-09       Impact factor: 11.205

8.  The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins.

Authors:  Saisai Wei; Hongbo Wang; Chunwan Lu; Sarah Malmut; Jianqiao Zhang; Shumei Ren; Guohua Yu; Wei Wang; Dale D Tang; Chunhong Yan
Journal:  J Biol Chem       Date:  2014-02-19       Impact factor: 5.157

9.  Heterozygosity for hypoxia inducible factor 1alpha decreases the incidence of thymic lymphomas in a p53 mutant mouse model.

Authors:  Jessica A Bertout; Shetal A Patel; Benjamin H Fryer; Amy C Durham; Kelly L Covello; Kenneth P Olive; Michael H Goldschmidt; M Celeste Simon
Journal:  Cancer Res       Date:  2009-03-17       Impact factor: 12.701

Review 10.  Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Authors:  Mark Wade; Geoffrey M Wahl
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.